Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylergonovine + oxytocin
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
A combination of two uterotonic agents used to prevent and control postpartum hemorrhage. Methylergonovine is an ergot alkaloid that acts directly on the smooth muscle of the uterus to increase tone, rate, and amplitude of rhythmic contractions. Oxytocin stimulates uterine contractions and helps the uterus return to its normal size after childbirth. The combination has an additive or synergistic effect in preventing postpartum hemorrhage compared to oxytocin alone.
- Brand names
- Syntometrine
- Other names
- oxytocin + methylergometrine
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)ADRA1A (α1A)DRD1 (Dopamine D1 Receptor)Oxytocin receptor
Beyond the preview
Go deeper on methylergonovine + oxytocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylergonovine + oxytocin.